We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
101
Madrigal Pharmaceuticals
MDGL
$11.8B
$494K 0.09%
+1,490
New +$490K
PCVX icon
102
Vaxcyte
PCVX
$8.64B
$483K 0.09%
+12,800
New +$1.02M
RNXT icon
103
RenovoRx
RNXT
$50.5M
$475K 0.09%
479,883
+282,633
+143% +$329K
ALEC icon
104
Alector
ALEC
$199M
$468K 0.09%
380,330
+12,000
+3% +$19.5K
INSM icon
105
Insmed
INSM
$28.6B
$463K 0.09%
6,074
-15,900
-72% -$1.22M
BNTX icon
106
BioNTech
BNTX
$23.5B
$455K 0.08%
+5,000
New +$560K
CDTX
107
DELISTED
Cidara Therapeutics
CDTX
$451K 0.08%
20,938
-4,000
-16% -$88.9K
TENX icon
108
Tenax Therapeutics
TENX
$503M
$450K 0.08%
68,741
+34,048
+98% +$218K
EWTX icon
109
Edgewise Therapeutics
EWTX
$4.73B
$440K 0.08%
+20,000
New +$525K
NETD
110
DELISTED
Nabors Energy Transition Corp II
NETD
$437K 0.08%
39,900
– –
GERN icon
111
Geron
GERN
$949M
$423K 0.08%
266,176
-71,500
-21% -$174K
TIL icon
112
Instil Bio
TIL
$50.3M
$422K 0.08%
24,328
-7,380
-23% -$153K
KALV
113
DELISTED
KalVista Pharmaceuticals
KALV
$412K 0.08%
35,743
-100
-0.3% -$1.02K
APLS
114
DELISTED
Apellis Pharmaceuticals
APLS
$372K 0.07%
17,000
+2,000
+13% +$55.3K
ARGX icon
115
argenx
ARGX
$54.1B
$355K 0.07%
+600
New +$379K
THRD
116
DELISTED
Third Harmonic Bio
THRD
$347K 0.06%
+100,000
New +$485K
ISRG icon
117
Intuitive Surgical
ISRG
$134B
$347K 0.06%
+700
New +$387K
BMRN icon
118
BioMarin Pharmaceuticals
BMRN
$12.4B
$346K 0.06%
+4,900
New +$330K
DNTH icon
119
Dianthus Therapeutics
DNTH
$6.09B
$332K 0.06%
18,285
+602
+3% +$13.3K
NGNE icon
120
Neurogene
NGNE
$712M
$327K 0.06%
+27,925
New +$485K
ESTA icon
121
Establishment Labs
ESTA
$2.28B
$326K 0.06%
+8,000
New +$298K
VTYX
122
DELISTED
Ventyx Biosciences
VTYX
$324K 0.06%
281,600
+157,070
+126% +$270K
JVSA
123
DELISTED
JV SPAC Acquisition Corp
JVSA
$322K 0.06%
30,000
– –
DYN icon
124
Dyne Therapeutics
DYN
$4.9B
$315K 0.06%
+30,099
New +$431K
OABI icon
125
OmniAb
OABI
$447M
$303K 0.06%
126,108
-152,000
-55% -$497K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.